The objectives of the pilot project core are to provide funding for innovative new research to test the hypotheses of investigators to generate preliminary data for future external grant submissions. Young investigators, those who have been funded by external sources for their work in the drug abuse field but have a new hypothesis that needs testing for its feasibility before seeking external funding, investigators who have been successful working in another area of biomedical research and have a hypothesis that utilizes that expertise to test a hypothesis in the drug abuse field. Collaborative projects among scholars from more than one of these groups will be given priority. Scholars from throughout the university will be encouraged to participate in this program and the Department of Pharmacology and Toxicology will provide matching funds for all pilot projects funded. The scholars funded by this mechanism will have an advantage in seeking support from the School of Medicine Research Funding, the campus-wide A.D. Williams Research Program and the Presidents Research Initiative Program. All levels of the university administration will continue to be committed to support drug abuse researchers through this center of excellence and these other mechanisms It is impressive that scholars supported by the pilot project programs in the past have had at least a three times higher success rate with their external applications than the national average.

Public Health Relevance

These pilot projects which will be innovative have great potential to provide new insights to mechanism to treat and prevent diseases of substance abuse. This type of program will encourage scholars who have proven expertise in other areas of biomedical research to contribute their expertise to this important area.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA033934-05
Application #
9388988
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
2019-05-31
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wolstenholme, Jennifer T; Bowers, M Scott; Pais, Alexander B et al. (2018) Dietary Omega-3 Fatty Acids Differentially Impact Acute Ethanol-Responsive Behaviors and Ethanol Consumption in DBA/2J Versus C57BL/6J Mice. Alcohol Clin Exp Res :
Hermes, Douglas J; Xu, Changqing; Poklis, Justin L et al. (2018) Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology 141:55-65
Mischel, Ryan A; Dewey, William L; Akbarali, Hamid I (2018) Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience 2:193-209
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2018) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm 15:721-728
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2018) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun 69:124-138
Curry, Zachary A; Wilkerson, Jenny L; Bagdas, Deniz et al. (2018) Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J Pharmacol Exp Ther 366:169-183
Cooper, Ziva D; Poklis, Justin L; Liu, Fei (2018) Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Neuropharmacology 134:92-100
Grim, T W; Morales, A J; Thomas, B F et al. (2017) Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model. J Pharmacol Exp Ther 362:210-218
Wilkerson, Jenny L; Ghosh, Sudeshna; Mustafa, Mohammed et al. (2017) The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. Neuropharmacology 114:156-167

Showing the most recent 10 out of 93 publications